Patent US4841804A successfully refreshed from Google Patents.
Patent US5804602A successfully refreshed from Google Patents.
US5804602A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of cancer treatment using naaladase inhibitors
Assignee: Eisai Inc
•
Filing: 1996-06-17
•
Granted: 1998-09-08
•
Expires: 2016-06-17
Abstract
Abstract The present invention is based upon the surprising discovery that NAALADase inhibitors exhibit a significant inhibitory effect on the growth of prostate cancer cells. The present disclosure relates to methods of treating diseases of the prostate, in particular prostate cancer, using novel compositions which inhibit N-Acetylated α-Linked Acidic Dipeptidase (NAALADase) enzyme activity in humans and warm-blooded animals. Furthermore, as NAALADase has been found in other tissues of the body it may serve as a cancer associated protein and thus NAALADase inhibitors would be expected to show efficacy in the treatment of other forms of cancer.
Inventors
- 👤 Barbara S. Slusher
- 👤 Paul F. Jackson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 06:26
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/661; A61K31/662; A61K31/664; A61K31/665; A61K31/67; A61K31/675; C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/30; C07F9/301; C07F9/38; C07F9/3804; C07F9/3808; C07F9/3826
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
25 words
A method of treating prostate tumor cell growth which comprises: administering to an animal suffering from a cancer an effective amount of a NAALADase inhibitor.
Claim 2
Independent Claim
25 words
A method of treating prostate tumor cell growth which comprises: administering to an animal suffering from a cancer an effective amount of a NAALADase inhibitor.
Claim 3
Dependent Claim
24 words
The method of claim 1 wherein the NAALADase inhibitor is selected from the group consisting of: 2-(phosphonomethyl)pentanedioic acid; 2-(phosphonomethyl)succinic acid; and 2- (2-carboxyethyl)hydroxyphosphinoyl!methyl!pentanedioic acid.
Claim 4
Dependent Claim
37 words
The method of claim 2 wherein the NAALADase inhibitor is administered in combination with an additional therapeutic agent selected from the group consisting of: therapeutic hormones, chemotherapeutic agents, monoclonal antibodies, anti-angiogenesis agents, radiolabelled compounds, and mixtures thereof.
Claim 5
Independent Claim
28 words
A method for inhibiting the growth of prostatic tumor cells in an animal which comprises: administering to said prostatic tumor cells an effective amount of a NAALADase inhibitor.
Claim 6
Independent Claim
28 words
A method for inhibiting the growth of prostatic tumor cells in an animal which comprises: administering to said prostatic tumor cells an effective amount of a NAALADase inhibitor.
Claim 7
Dependent Claim
24 words
The method of claim 4 wherein the NAALADase inhibitor is selected from the group consisting of: 2-(phosphonomethyl)pentanedioic acid; 2-(phosphonomethyl)succinic acid; and 2- (2-carboxyethyl)hydroxyphosphinoyl!methyl!pentanedioic acid.
Claim 8
Dependent Claim
37 words
The method of claim 5 wherein the NAALADase inhibitor is administered in combination with an additional therapeutic agent selected from the group consisting of: therapeutic hormones, chemotherapeutic agents, monoclonal antibodies, anti-angiogenesis agents, radiolabelled compounds, and mixtures thereof.
Claim 9
Independent Claim
34 words
A method of treating prostate diseases selected from the group consisting of prostate cancer and benign prostatic hyperplasia in an animal, which comprises: administering to said animal an effective amount of a NAALADase inhibitor.
Claim 10
Independent Claim
34 words
A method of treating prostate diseases selected from the group consisting of prostate cancer and benign prostatic hyperplasia in an animal, which comprises: administering to said animal an effective amount of a NAALADase inhibitor.
Claim 11
Dependent Claim
24 words
The method of claim 7 wherein the NAALADase inhibitor is selected from the group consisting of: 2-(phosphonomethyl)pentanedioic acid; 2-(phosphonomethyl)succinic acid; and 2- (2-carboxyethyl)hydroxyphosphinoyl!methyl!pentanedioic acid.
Claim 12
Dependent Claim
37 words
The method of claim 8 wherein the NAALADase inhibitor is administered in combination with an additional therapeutic agent selected from the group consisting of: therapeutic hormones, chemotherapeutic agents, monoclonal antibodies, anti-angiogenesis agents, radiolabelled compounds, and mixtures thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-09-07 | 2002-03-09 | 2002-09-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-09-07 | 2006-03-09 | 2006-09-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-09-07 | 2010-03-09 | 2010-09-08 | $7700.00 | Window Closed / Lapsed |